A Population Health Approach to Lipid Management: Primary Care Guidance Speakers

Promotional series organised and fully funded by Novartis Pharmaceuticals UK Ltd.

Dr Jim Moore //
Dr Jim Moore
President of the Primary Care Cardiovascular Society, GP, GPSI Cardiology, Gloucestershire

Dr Moore studied medicine in Edinburgh before moving to Gloucestershire to work as a GP principal. He has an interest in cardiology and cardiovascular disease, particularly those aspects that are relevant to primary care and contributes regularly to related educational events across the UK. He is President of the primary care cardiovascular society.

Dr Moore was involved in the development of the Primary Care based Gloucestershire Heart Failure service where he continues to work as a GPwSI.

He continues to represent Primary Care in the cardiovascular area at both a local and national level. He has provided cardiovascular clinical support to local commissioning organisations for over ten years and remains actively involved in commissioning local cardiology services chairing the Circulatory Clinical Programme Group for Gloucestershire Clinical Commissioning Group (CCG). He was Clinical Lead for the community based West of England AHSN Stroke Prevention in AF project: Don’t wait to anticoagulate.

Dr Moore previously served on the board of the British Society for Heart Failure and was a member of the NICE Chronic Heart Failure Guideline committee (2018). He currently sits on the National Heart Failure Audit Steering group.

Sotiris Antoniou //
Sotiris Antoniou
Consultant Pharmacist, Cardiovascular Medicine at Barts Health NHS Trust and Lead Cardiovascular Pharmacist, UCL Partners, AHSN

Sotiris is Head of Pharmacy at St Bartholomew’s Hospital, a specialist tertiary referral centre for Cardiovascular, Oncology and respiratory services and Consultant Pharmacist at Barts Heart Centre, part of Barts Health NHS Trust. Combined with his role as Clinical Advisor for UCL Partners supports medicines optimisation across the health economy to optimise patient outcomes and address unmet local needs.

Sotiris has published extensively in the medical press and is actively involved in the training and development of clinical pharmacists. He has recently obtained NHSE Pathway transformation funding to provide a specialist Cardiovascular pharmacist working collaboratively with primary care to improve lipid modification across the locality.

Sotiris is on the board of ESC ACNAP (Association of Cardiovascular Nursing and Allied Professionals) and has served on many NICE development groups including Unstable Angina/NSTEMI guideline, stable angina and STEMI guidelines and is a current NICE TA member of the highly specialist technology appraisal group. Sotiris is also an adjunct Assistant Professor at Purdue University, USA.

Dr Peter Carey //
Dr Peter Carey
Consultant Physician in Diabetes and Endocrinology, South Tyneside and Sunderland NHSFT and Honorary Clinical Lecturer, University of Sunderland Medical School

Dr Peter Carey is a consultant in Diabetes and Endocrinology at South Tyneside and Sunderland and Regional Lipid Advisor to the Academic Health Sciences Network –North East and North Cumbria.

He qualified from the University of Sheffield and trained initially in Liverpool before returning to the North East to undertake his MD in postprandial metabolism in type 2 diabetes and complete his specialty training.

His main clinical interests are Lipidology, Type 1 Diabetes and Thyroid disorders. He is actively involved as an Honorary Lecturer in undergraduate teaching at the University of Sunderland Medical School.

His work with the AHSN-NENC involves the implementation of the NHS England Cardiovascular Disease Prevention Programme through lipid optimisation, increased use of emerging therapies and identifying individuals with Familial Hypercholesterolaemia through the use of primary care data searches.

MLR ID: 221550 | September 2022

Adverse Event Reporting:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com

If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com